[go: up one dir, main page]

AU2005248149A1 - Viral and viral associated miRNAs and uses thereof - Google Patents

Viral and viral associated miRNAs and uses thereof Download PDF

Info

Publication number
AU2005248149A1
AU2005248149A1 AU2005248149A AU2005248149A AU2005248149A1 AU 2005248149 A1 AU2005248149 A1 AU 2005248149A1 AU 2005248149 A AU2005248149 A AU 2005248149A AU 2005248149 A AU2005248149 A AU 2005248149A AU 2005248149 A1 AU2005248149 A1 AU 2005248149A1
Authority
AU
Australia
Prior art keywords
mirna
nucleic acid
sequence
expression
probes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005248149A
Other languages
English (en)
Inventor
Ranit Aharonov
Amir Avniel
Itzhak Bentwich
Yael Karov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rosetta Genomics Ltd
Original Assignee
Rosetta Genomics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/709,739 external-priority patent/US7777022B2/en
Application filed by Rosetta Genomics Ltd filed Critical Rosetta Genomics Ltd
Publication of AU2005248149A1 publication Critical patent/AU2005248149A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16221—Viruses as such, e.g. new isolates, mutants or their genomic sequences

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
AU2005248149A 2004-05-26 2005-05-26 Viral and viral associated miRNAs and uses thereof Abandoned AU2005248149A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US10/709,739 US7777022B2 (en) 2002-12-05 2004-05-26 Bioinformatically detectable group of novel regulatory viral and viral associated oligonucleotides and uses thereof
US10/709,739 2004-05-26
US52245104P 2004-10-03 2004-10-03
US52245004P 2004-10-03 2004-10-03
US60/522,450 2004-10-03
US60/522,451 2004-10-03
US52245904P 2004-10-04 2004-10-04
US60/522,459 2004-10-04
US66509405P 2005-03-25 2005-03-25
US60/665,094 2005-03-25
PCT/IB2005/002352 WO2005116250A2 (fr) 2004-05-26 2005-05-26 Arnmi viraux ou associes aux virus et leur utilisation

Publications (1)

Publication Number Publication Date
AU2005248149A1 true AU2005248149A1 (en) 2005-12-08

Family

ID=42331989

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005248149A Abandoned AU2005248149A1 (en) 2004-05-26 2005-05-26 Viral and viral associated miRNAs and uses thereof

Country Status (7)

Country Link
EP (1) EP1751311A2 (fr)
JP (1) JP2008500039A (fr)
CN (1) CN101031658A (fr)
AU (1) AU2005248149A1 (fr)
CA (1) CA2567937A1 (fr)
IL (1) IL179545A (fr)
WO (1) WO2005116250A2 (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040219565A1 (en) 2002-10-21 2004-11-04 Sakari Kauppinen Oligonucleotides useful for detecting and analyzing nucleic acids of interest
US8071306B2 (en) 2005-01-25 2011-12-06 Merck Sharp & Dohme Corp. Methods for quantitating small RNA molecules
ATE480644T1 (de) * 2005-01-25 2010-09-15 Rosetta Inpharmatics Llc Verfahren zur quantifizierung kleiner rna- moleküle
AU2006254732A1 (en) * 2005-06-03 2006-12-07 Southern Adelaide Health Service-Flinders Medical Centre Targeting cells with altered microrna expression
WO2007113388A2 (fr) * 2006-03-31 2007-10-11 Licentia Oy Procédé et microréseau destinés à la détection de virus de l'herpès
US8007790B2 (en) 2006-04-03 2011-08-30 Stowers Institute For Medical Research Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
US7727725B2 (en) 2006-04-27 2010-06-01 Celera Corporation Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof
JP2010500867A (ja) * 2006-06-30 2010-01-14 ロゼッタ ジノミクス リミテッド 核酸の検出方法
US8227590B2 (en) 2006-11-21 2012-07-24 Jawaharlal Nehru Centre For Advanced Scientific Research High sensitivity assay for molecular typing of biological sample, probes and a kit thereof
SG143090A1 (en) * 2006-11-27 2008-06-27 Agency Science Tech & Res Influenza b virus detection method and kit therefor
US8481506B2 (en) 2006-12-05 2013-07-09 Rosetta Genomics, Ltd. Nucleic acids involved in viral infection
EP2387616A2 (fr) * 2009-01-16 2011-11-23 Cepheid Procédés de détection de cancers du col de l'utérus
US20100240049A1 (en) 2009-01-16 2010-09-23 Cepheid Methods of Detecting Cervical Cancer
US20140148348A1 (en) 2010-01-13 2014-05-29 Christine Kuslich Dectection of gastrointestinal disorders
AU2011205863B2 (en) * 2010-01-18 2014-08-28 Universiteit Utrecht Holding B.V. Means and methods for distinguishing FECV and FIPV
AU2011223789A1 (en) 2010-03-01 2012-09-20 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
KR101886457B1 (ko) 2010-10-06 2018-08-07 큐알엔에이, 인크. 시알리다아제 4 (neu4)에 대한 자연 안티센스 전사체의 저해에 의한 neu4 관련된 질환의 치료
EP2756080B1 (fr) 2011-09-14 2019-02-20 Translate Bio MA, Inc. Composés oligonucléotidiques multimères
US20130302784A1 (en) * 2012-03-30 2013-11-14 Intelligent Medical Devices, Inc. Optimized probes and primers and methods of using same for the binding, detection, differentiation, isolation and sequencing of herpes simplex virus
AU2013205110B2 (en) * 2012-04-24 2016-10-13 Gen-Probe Incorporated Compositions, Methods and Kits to Detect Herpes Simplex Virus Nucleic Acids
US11033620B2 (en) 2014-06-09 2021-06-15 Biomed Valley Discoveries, Inc. Combination therapies targeting tumor-associated stroma or tumor cells and microtubules
WO2015191617A2 (fr) 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Polythérapies utilisant des anti-métabolites et des agents qui ciblent un stroma associé à une tumeur ou des cellules tumorales
WO2015191610A2 (fr) 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Polythérapies utilisant des agents qui ciblent un stroma associé à une tumeur ou des cellules tumorales et d'autres voies
US10758614B2 (en) 2014-06-09 2020-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Institutes Of Health Combination therapies targeting tumor-associated stroma or tumor cells and topoisomerase
US11034757B2 (en) 2014-06-09 2021-06-15 Biomed Valley Discoveries, Inc. Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature
US10434174B2 (en) 2014-06-09 2019-10-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination therapies using platinum agents and agents that target tumor-associated stroma or tumor cells
US10556020B2 (en) 2014-09-26 2020-02-11 University Of Massachusetts RNA-modulating agents
WO2016130943A1 (fr) 2015-02-13 2016-08-18 Rana Therapeutics, Inc. Oligonucléotides hybrides et leurs utilisations
WO2017004079A1 (fr) 2015-06-29 2017-01-05 Biomed Valley Discoveries, Inc. Combinaison d'inhibiteurs de lpt-723 et de point de contrôle immunitaire et méthodes de traitement
WO2017134529A1 (fr) * 2016-02-02 2017-08-10 Crispr Therapeutics Ag Substances et méthodes pour le traitement d'une immunodéficience combinée sévère (idcs) ou syndrome d'omenn
KR20190017872A (ko) 2016-06-08 2019-02-20 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 염증 및 면역 반응 유도를 감소시키는 조작된 바이러스 벡터
US11053496B2 (en) * 2016-06-14 2021-07-06 Agency For Science, Technology And Research Consequences of a defective switch in cutaneous squamous cell carcinoma
EP3661924A1 (fr) 2017-07-31 2020-06-10 The Trustees of Columbia University in the City of New York Composés, compositions et procédés de traitement de la leucémie lymphoblastique aiguë à lymphocytes t
KR20200085812A (ko) 2017-11-08 2020-07-15 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 바이러스 벡터-유도된 염증 반응을 억제하기 위한 조성물 및 방법
AU2019258585A1 (en) * 2018-04-23 2020-11-26 BiomeMega Pty Ltd A microbial sanitiser with broad applications
WO2019226832A1 (fr) 2018-05-22 2019-11-28 Jie Shen Thérapie génique pour la maladie d'alzheimer
US11866705B2 (en) 2018-07-31 2024-01-09 Osaka Univerity Small cell lung cancer therapeutic agent containing oligonucleotide
EP3853364A1 (fr) * 2018-09-18 2021-07-28 Alnylam Pharmaceuticals, Inc. Compositions d'arni de cétohexokinase (khk) et leurs procédés d'utilisation
MX2022006499A (es) 2019-11-29 2022-08-15 Paros Bio Inc Terapia genica para trastornos neurodegenerativos.
AU2021213253A1 (en) * 2020-01-31 2022-09-08 Paros Bio, Inc. Gene therapy for neurodegenerative disorders using polynucleotide silencing and replacement
AU2022226098A1 (en) 2021-02-26 2023-08-24 Alnylam Pharmaceuticals, Inc. KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
JP7536187B2 (ja) 2021-04-19 2024-08-19 ノヴォ ノルディスク アー／エス 核内受容体サブファミリー１グループｈメンバー３（ｎｒ１ｈ３）発現を阻害するための組成物および方法
DE112022004237T5 (de) * 2021-09-03 2024-07-04 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung eingetragener Verein DNA-Aptamere und ihre Verwendung in der (Vor-)Diagnose von Krebs
US11898186B1 (en) 2022-08-10 2024-02-13 Genscript Usa Inc. Compositions and methods for preparing capped mRNA

Also Published As

Publication number Publication date
WO2005116250A8 (fr) 2007-07-05
EP1751311A2 (fr) 2007-02-14
JP2008500039A (ja) 2008-01-10
IL179545A0 (en) 2007-05-15
WO2005116250A2 (fr) 2005-12-08
CA2567937A1 (fr) 2005-12-08
WO2005116250A3 (fr) 2006-07-06
CN101031658A (zh) 2007-09-05
IL179545A (en) 2010-12-30

Similar Documents

Publication Publication Date Title
US9624556B2 (en) Viral and viral associated miRNAs and uses thereof
AU2005248149A1 (en) Viral and viral associated miRNAs and uses thereof
AU2005243410B2 (en) Micronas and uses thereof
US7642348B2 (en) Prostate cancer-related nucleic acids
US7592441B2 (en) Liver cancer-related nucleic acids
US7825229B2 (en) Lung cancer-related nucleic acids
WO2009024834A2 (fr) Acides nucléiques impliques dans les infections virales
US20110189766A1 (en) Micrornas and uses thereof
US20070166724A1 (en) Micrornas and related nucleic acids
US20070259349A1 (en) Bladder cancer-related nucleic acids

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: ADD CO-INVENTORS AHARONOV, RANIT AND KAROV, YAEL

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application